89 related articles for article (PubMed ID: 21751886)
1. Metastatic medullary thyroid cancer presenting with elevated levels of CA 19-9 and CA 125.
Milman S; Whitney KD; Fleischer N
Thyroid; 2011 Aug; 21(8):913-6. PubMed ID: 21751886
[TBL] [Abstract][Full Text] [Related]
2. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
3. Pancreas cancer-associated antigen (PCAA) in medullary thyroid carcinoma.
Ueno K; Kobayashi T; Shimano T; Matsuura N; Monden T; Takeda T; Tomita N; Mori T
Med J Osaka Univ; 1994 Sep; 43(1-4):17-21. PubMed ID: 7609706
[TBL] [Abstract][Full Text] [Related]
4. Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report.
Elisei R; Lorusso L; Romei C; Bottici V; Mazzeo S; Giani C; Fiore E; Torregrossa L; Insilla AC; Basolo F; Guerini A; Menghi A; Poletti A; Cugudda L; Vitti P
J Clin Endocrinol Metab; 2013 Sep; 98(9):3550-4. PubMed ID: 23861463
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
Milone F; Ramundo V; Chiofalo MG; Severino R; Paciolla I; Pezzullo L; Lombardi G; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2010 Jul; 73(1):85-8. PubMed ID: 20039894
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
7. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes.
Skinner MA; Wells SA
Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335
[TBL] [Abstract][Full Text] [Related]
8. Ghrelin in human medullary thyroid carcinomas.
Morpurgo PS; Cappiello V; Verga U; Vicentini L; Vaghi I; Lauri E; Nebuloni M; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):437-41. PubMed ID: 16181236
[TBL] [Abstract][Full Text] [Related]
9. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
[TBL] [Abstract][Full Text] [Related]
10. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid carcinoma.
Pacini F; Castagna MG; Cipri C; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
[TBL] [Abstract][Full Text] [Related]
12. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
13. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
[TBL] [Abstract][Full Text] [Related]
14. Presentation of a medullary endocrine neoplasia 2A kindred with Cushing's syndrome.
Zaydfudim V; Stover DG; Caro SW; Phay JE
Am Surg; 2008 Jul; 74(7):659-61. PubMed ID: 18646485
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid carcinoma experienced at Kanazawa University Hospital.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Ohtake S; Nakamura S; Ishizaki T
J Surg Oncol; 1996 Jan; 61(1):27-33. PubMed ID: 8544456
[TBL] [Abstract][Full Text] [Related]
16. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
17. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature.
Bhanot P; Yang J; Schnadig VJ; Logroño R
Diagn Cytopathol; 2007 May; 35(5):285-92. PubMed ID: 17427218
[TBL] [Abstract][Full Text] [Related]
18. [Multiple endocrine type 2 neoplasia in 3 families].
Palchik M; Sánchez A; Góméz J; Rodríguez Pécora A
Medicina (B Aires); 1990; 50(2):117-23. PubMed ID: 1983220
[TBL] [Abstract][Full Text] [Related]
19. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
Pelizzo MR; Boschin IM; Bernante P; Toniato A; Piotto A; Pagetta C; Nibale O; Rampin L; Muzzio PC; Rubello D
Eur J Surg Oncol; 2007 May; 33(4):493-7. PubMed ID: 17125960
[TBL] [Abstract][Full Text] [Related]
20. Familial nonmultiple endocrine neoplasia medullary thyroid carcinoma: an evolving clinical entity.
McHenry CR; Oppenheim DS; Murphy T; Broughan T; Vogt D; Goldfarb WB
Surgery; 1992 Oct; 112(4):728-32; discussion 732-3. PubMed ID: 1411944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
